ABT 981

Drug Profile

ABT 981

Alternative Names: ABT-981

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie
  • Class Bispecific antibodies; Immunoglobulins; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Interleukin 1 alpha inhibitors; Interleukin 1 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Osteoarthritis

Most Recent Events

  • 01 Dec 2016 AbbVie completes a phase IIa trial for Osteoarthritis (of the knee) in USA, Australia, Canada, Denmark, France, Italy, Mexico, Netherlands, Puerto Rico, Spain and United Kingdom (NCT02087904)
  • 15 Jul 2016 AbbVie completes a phase IIa trial for Osteoarthritis (of the hand) in USA, Belgium, Denmark, France, Netherlands and Switzerland (NCT02384538)
  • 09 Jul 2015 Phase II clinical trials in Osteoarthritis (of the hand and knee) in Netherlands (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top